Xeris Biopharma Holdings, Inc. (XERS)
XERS Stock Price Chart
Explore Xeris Biopharma Holdings, Inc. interactive price chart. Choose custom timeframes to analyze XERS price movements and trends.
XERS Company Profile
Discover essential business fundamentals and corporate details for Xeris Biopharma Holdings, Inc. (XERS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2018
Employees
394.00
Website
https://www.xerispharma.comCEO
John Shannon
Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS Financial Timeline
Browse a chronological timeline of Xeris Biopharma Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.02, while revenue estimate is $90.29m.
Earnings released on 7 May 2026
EPS came in at $0.01 surpassing the estimated -$0.00 by +464.96%, while revenue for the quarter reached $82.45m , beating expectations by +3.28%.
Earnings released on 2 Mar 2026
EPS came in at $0.06 surpassing the estimated $0.03 by +100.00%, while revenue for the quarter reached $85.81m , beating expectations by +4.39%.
Earnings released on 6 Nov 2025
EPS came in at $0.00 falling short of the estimated $0.01 by -65.00%, while revenue for the quarter reached $74.38m , missing expectations by -13.51%.
Earnings released on 7 Aug 2025
EPS came in at -$0.01 surpassing the estimated -$0.03 by +66.67%, while revenue for the quarter reached $71.54m , missing expectations by -0.98%.
Earnings released on 8 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $60.12m , beating expectations by +4.36%.
Earnings released on 6 Mar 2025
EPS came in at -$0.03 surpassing the estimated -$0.08 by +62.50%, while revenue for the quarter reached $60.10m , beating expectations by +9.47%.
Earnings released on 8 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $54.27m , beating expectations by +5.52%.
Earnings released on 8 Aug 2024
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $48.07m , beating expectations by +4.92%.
Earnings released on 9 May 2024
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $40.64m , missing expectations by -2.81%.
Earnings released on 6 Mar 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $44.39m , missing expectations by -3.10%.
Earnings released on 9 Nov 2023
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $48.32m , beating expectations by +13.16%.
Earnings released on 8 Aug 2023
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%, while revenue for the quarter reached $38.01m , beating expectations by +8.11%.
Earnings released on 9 May 2023
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $33.20m , beating expectations by +6.97%.
Earnings released on 8 Mar 2023
EPS came in at -$0.10 surpassing the estimated -$0.16 by +37.50%, while revenue for the quarter reached $33.14m , beating expectations by +7.04%.
Earnings released on 9 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $29.73m , beating expectations by +2.35%.
Earnings released on 10 Aug 2022
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%, while revenue for the quarter reached $25.31m , missing expectations by -38.40%.
Earnings released on 11 May 2022
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%, while revenue for the quarter reached $22.07m , missing expectations by -5.64%.
Earnings released on 10 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.21 by -100.00%, while revenue for the quarter reached $21.43m , beating expectations by +12.94%.
Earnings released on 10 Nov 2021
EPS came in at -$0.36 surpassing the estimated -$0.37 by +2.70%, while revenue for the quarter reached $11.04m , beating expectations by +0.23%.
Earnings released on 5 Aug 2021
EPS came in at -$0.41 falling short of the estimated -$0.31 by -32.26%, while revenue for the quarter reached $8.91m , meeting expectations.
XERS Stock Performance
Access detailed XERS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
